RaySearch Laboratories AB (publ) logo

RaySearch Laboratories AB (publ)

RAY-B.ST
55
Medical - Healthcare Information Services · Healthcare
Price
kr 220.20
+6.80 (+3.19%)
Market Cap
kr 7.55B
Exchange
Stockholm Stock Exchange
Winston Score
55
Winston looking curious
Winston is curious
A decent business — some strong pillars, some weaker.

Winston Score between 40 and 70. The stock passes some quality checks but not all.

RaySearch Laboratories is a Swedish software company that makes treatment planning software for cancer radiation therapy. Its main product, RayStation, is used by hospitals and cancer clinics to calculate and plan how radiation beams should be targeted at tumors. The company does not make radiation machines itself — it makes the software that controls how those machines are used.

RaySearch earns money through software licenses and ongoing maintenance fees paid by hospitals, which creates a recurring revenue stream. It operates globally, with customers in over 30 countries across Europe, North America, and Asia. Its competitive position is strong because treatment planning software is deeply embedded in clinical workflows, making it costly and disruptive for hospitals to switch providers. The key growth driver is the rising global demand for cancer treatment, particularly in emerging markets where radiation therapy infrastructure is still being built out — though the main risk is competition from larger medical device companies like Varian and Elekta, which offer competing software bundled with their own hardware.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-12.5% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-6.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$270M/ year

Flat (+0% vs prior year)

20.1% of revenue

In line with sector average (18%)

Steady R&D investment year-over-year

Insider Activity

22.8%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$439M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Winston looking concerned
Revenue declining

RaySearch Laboratories AB (publ)'s revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
68.1%
Premium pricing power — 68.1% gross margin
Operating Margin
18.6%
Healthy — 18.6% operating margin
ROCE
4.8%
Weak — 4.8% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+2.9%
Nearly flat sales (2.9% YoY)
EPS YoY
+0.3%
Flat earnings

Single-digit earnings growth — steady but not exciting.

EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
156%
Turns 156% of profit into real cash
FCF Margin
17.8%
Converts sales into free cash efficiently (17.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.08
Conservative — low debt load (0.08)
Interest Cover
72.09x
Comfortably covers interest (72.1x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio
29.2x
Growth-priced — P/E 29.2

P/E above the market average. People are paying up for expected growth.

P/E vs Forward
+1.2
GROWING
Earnings expected to grow — slightly cheaper on forward P/E

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
1.82%
Small dividend — 1.82% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth
N/A
no trend
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial